Loading...
•
Jun 30, 2020
Replimune Q1 2021 Earnings Report
Replimune's clinical proof of principle was established with RP1 in combination with Opdivo for immune-responsive tumors, supporting registration-directed development in CSCC and anti-PD1 refractory melanoma. The pipeline progressed, and initial single agent data with RP2 for less immune-responsive tumors is expected in the fourth calendar quarter, with RP3 expected to enter the clinic by year-end. The management team was strengthened with the appointment of Andrea Pirzkall, M.D. as Chief Medical Officer. Gross proceeds of $115 million were raised through a public offering, strengthening the balance sheet and extending the cash runway to mid-2023.
Key Takeaways
Replimune Group, Inc. reported financial results for the fiscal first quarter ended June 30, 2020. Clinical proof of principle was established with RP1 in combination with Opdivo for immune-responsive tumors, supporting registration-directed development in CSCC and anti-PD1 refractory melanoma. The company raised gross proceeds of $115 million through a public offering, extending the cash runway to mid-2023.
Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 refractory melanoma.
Pipeline progressing; initial single agent data with RP2 for less immune-responsive tumors expected to be presented in the fourth calendar quarter with RP3 expected to enter the clinic by the year end
Management team strengthened with the appointment of Andrea Pirzkall, M.D. as Chief Medical Officer
Raised gross proceeds of $115 million through a public offering; strengthened balance sheet allows for additional studies and extension of cash runway to mid-2023
Replimune
Replimune
Forward Guidance
The company believes that the existing cash and cash equivalents and short-term investments, along with a limited use of debt, will enable the Company to fund additional studies and the overall operating plan to mid-2023.